Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb (BMY) Reiterated at Neutral by Cantor Fitzgerald on Eliquis Outlook

April 8, 2026 7:33 AM
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $54.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments